← Back to Analyst Consensus 
BRVE Buy
Braveheart Bio, Inc.
Current Price —
Implied Upside —
Analysts 11
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 1 reiterations from 1 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 20, 2026 | Cantor Fitzgerald | reiterate | Overweight → Overweight | — | 50% |
Price Target Trend
Sep 3, 2026 Oct 26, 2026
EPS Estimates
+1q —
0y —
0q —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days